Sciele Home Sciele Products Page Product Development Pipeline Sciele Business Development Sciele Investor Relations Sciele Career Page Sciele Contact Information
 

PSD502 for Premature Ejaculation

Press Releases:

Sciele Pharma and Plethora Solutions Holdings PLC Announce Initiation of Pivotal Phase III Trials for PSD502 for Premature Ejaculation

Sciele Enters Into Exclusive License Agreement with Plethora Solutions Limited to Market PSD502 for the Treatment of Premature Ejaculation

Presentations:

 

Back to Pipeline

Adobe® Reader® is required to view our Prescribing Information documents;
click here to download this free program.

This web site and its contents are intended for use only by residents of the United States. Products discussed may have different labeling, regulatory requirements, and/or medical practices in other countries that may require reference to different or additional information.